Literature DB >> 6932177

Acute promyelocytic leukemia--clinical management of 15 patients.

P A Daly, C A Schiffer, P H Wiernik.   

Abstract

Fifteen patients with acute promyelocytic leukemia (APL) were treated with anthracycline agents alone or combined with arabinosylcytosine (Ara C). Disseminated intravascular coagulation (DIC) was managed individually based on the presence of clinical as well as laboratory evidence of DIC. Ten patients received heparin. Eleven patients (73%) achieved complete remission (CR) but there were two early deaths from infection. The median duration of CR was 232 days (range, 41-780 days). Six patients were studied during ten relapses. In all cases, a morphologic picture more typical of acute myelocytic leukemia was seen during relapse but the DIC was similar in severity to that seen initially. Fever, without obvious infection and possibly due to the leukemic process, was a common presenting feature. Regenerating bone marrow aspirates in many patients who subsequently achieved CR without further treatment showed an inordinate number of promyelocytes, and this finding should not be immediately interpreted as disease resistant to therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6932177     DOI: 10.1002/ajh.2830080403

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  7 in total

Review 1.  Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.

Authors:  Peter H Wiernik
Journal:  Med Oncol       Date:  2014-07-22       Impact factor: 3.064

Review 2.  Acute promyelocytic leukaemia in the all trans retinoic acid era.

Authors:  T G DeLoughery; S H Goodnight
Journal:  Med Oncol       Date:  1996-12       Impact factor: 3.064

3.  Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia.

Authors:  I Pabinger; P Bettelheim; R Dudczak; W Hinterberger; P A Kyrle; H Niessner; I Schwarzinger; W Speiser; K Lechner
Journal:  Ann Hematol       Date:  1991-05       Impact factor: 3.673

Review 4.  Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.

Authors:  E M Calleja; R P Warrell
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

Review 5.  Acute promyelocytic leukemia: where did we start, where are we now, and the future.

Authors:  C C Coombs; M Tavakkoli; M S Tallman
Journal:  Blood Cancer J       Date:  2015-04-17       Impact factor: 11.037

Review 6.  History of Acute Promyelocytic Leukemia.

Authors:  Miguel A Sanz; Eva Barragán
Journal:  Clin Hematol Int       Date:  2021-07-19

Review 7.  Hematologic and oncologic complications in the critically ill child.

Authors:  S McIntosh
Journal:  Yale J Biol Med       Date:  1984 Mar-Apr
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.